Fuda Cancer Hospital
Fuda Cancer Hospital
China, Kanton
Ewing's sarcoma treatment cost in China typically runs from $75,000 to $140,000 for complex multimodal care. Essential diagnostics like a complete blood count range from $100 to $100, while primary radiation therapy for sarcomas costs $10,500 to $21,700. Total expenses depend on the treatment stage, surgical technology, and clinic tier. Patients often save 50% to 70% compared to the United States. Top treatment hubs include Guangzhou, Shanghai, and Beijing.
Typical Ewing's Sarcoma Treatment Costs in China
Bookimed Expert Insight: Patients with advanced or late-stage Ewing's sarcoma benefit from multidisciplinary care at JCI-accredited centers. Fuda Cancer Hospital in Guangzhou specializes in minimally invasive alternatives to standard chemotherapy, utilizing technologies like NanoKnife and cryosurgery. For those requiring precision radiation, expert-led teams provide IMRT and VMAT protocols. Choosing centers with high international patient volumes ensures access to coordinated, multi-step regimens at competitive rates.
| China | Türkei | Österreich | |
| Strahlentherapie bei Sarkomen | von $10,500 | von $3,250 | von $18,000 |
| Strahlentherapie bei Darmkrebs | von $11,500 | von $7,000 | von $12,000 |
| Sarkom-Operation | von $16,500 | von $10,000 | von $35,000 |
| Komplexe Behandlung des Ewing-Sarkoms | von $75,000 | von $30,000 | von $55,000 |
| Knochenresektion | von $9,500 | von $8,000 | von $25,000 |
Bookimed erhebt keine zusätzlichen Gebühren für Ewing-Sarkom-Behandlungspreise. Die Preise stammen aus den offiziellen Preislisten der Kliniken. Sie zahlen direkt in der Klinik für Ihre Behandlung bei Ihrer Ankunft im Land.
Bookimed setzt sich für Ihre Sicherheit ein. Wir arbeiten nur mit medizinischen Einrichtungen zusammen, die hohe internationale Standards bei der Behandlung von Ewing-Sarkom einhalten und über die notwendigen Lizenzen verfügen, um internationale Patienten weltweit zu behandeln.
Bookimed bietet kostenlose fachliche Unterstützung. Ein persönlicher medizinischer Koordinator unterstützt Sie vor, während und nach Ihrer Behandlung und hilft Ihnen bei allen Fragen. Sie sind auf Ihrer Ewing-Sarkom-Behandlungsreise nie allein.
Professor Shixin Liu, MD, PhD, ist Fachbereichsleiter des Onkologiezentrums. Zuvor war er Präsident des Krebskrankenhauses der Provinz Jilin und Direktor des Forschungsinstituts für Krebsprävention und -therapie. Er ist Professor der zweiten Ebene und Promotionsbetreuer. Er erhielt die Sonderzulage des Staatsrats, die 4. Auszeichnung 'National Famous Doctor (Outstanding Contribution)' sowie den Ehrentitel 'Vorbild ärztlicher Ethik'.
Er ist auf die umfassende Diagnostik und Behandlung bösartiger Tumoren spezialisiert, mit Schwerpunkt auf präziser Strahlentherapie thorakaler und abdomineller Tumoren. Er beherrscht IMRT, VMAT und SBRT bei Lungen-, Speiseröhren-, Brust- und Rektumkarzinomen.
Zu seinen Leitungsfunktionen zählen die stellvertretenden Vorsitzämter bei CMA Radiation Oncology, CACA Radiotherapy und CACA Particle Therapy. Er gehört dem Ständigen Ausschuss der CSCO an und ist stellvertretender Vorsitzender des CSCO-Expertenkomitees für Strahlenonkologie. Zudem ist er stellvertretender Vorsitzender der CPAM Radiation Oncology und Mitglied des Ständigen Ausschusses der CSMEA. Er ist Vorsitzender der Sektion Strahlenonkologie der Jilin Medical Association. Er gehört den Redaktionsbeiräten des Chinese Journal of Radiation Oncology und des Practical Journal of Cancer an.
Ewing sarcoma treatment in China follows a multimodal protocol of systemic chemotherapy, surgical resection, and radiation therapy. Chinese centers utilize international standards from the Chinese Society of Clinical Oncology. Specific regimens include alternating VDC and IE chemotherapy cycles to target the primary tumor and micrometastases.
Bookimed Expert Insight: While major centers follow international guidelines, JCI-accredited facilities like Fuda Cancer Hospital offer unique minimally invasive alternatives. They utilize technologies like NanoKnife and cryosurgery for advanced cases. This allows for localized tumor destruction in patients who cannot tolerate traditional aggressive surgery or high-dose chemotherapy cycles.
Patient Consensus: Patients emphasize traveling to high-volume metropolitan centers for accurate pathology and molecular testing. They note that starting neoadjuvant chemotherapy quickly is vital given the aggressive nature of this sarcoma.
China offers advanced local therapies for sarcomas. These include cryosurgery, NanoKnife, and carbon ion radiotherapy. Specialized centers utilize High-Intensity Focused Ultrasound (HIFU) for non-invasive treatment. These techniques target complex tumors while preserving healthy tissue and critical structures near the tumor site.
Bookimed Expert Insight: Fuda Cancer Hospital stands out for managing late-stage cases using unique combinations. They integrate cryosurgery with vascular interventional therapy for difficult tumors. This approach is particularly valuable for patients from over 100 countries. It serves those whose tumors are considered unresectable in other regions.
Patient Consensus: Patients value the availability of proton therapy for protecting the spine and pelvis. They emphasize that the best results come from teams combining orthopedic oncology with reconstruction specialists.
Top hospitals in China for Ewing's sarcoma include elite institutions like Fuda Cancer Hospital and Beijing Jishuitan Hospital. Specialized centers focus on limb-sparing operations and advanced radiation. These facilities maintain Joint Commission International (JCI) accreditation. They utilize multidisciplinary teams for coordinated chemotherapy, surgery, and radiotherapy protocols.
Bookimed Expert Insight: Coordination between pediatric and orthopedic departments is the strongest quality signal in Chinese centers. Fuda Cancer Hospital manages over 30,000 international patients by offering over 10 types of minimally invasive therapies. This specialized focus on non-systemic treatments provides options for cases where traditional heavy chemotherapy is difficult.
Patient Consensus: Patients emphasize finding a dedicated orthopedic oncology unit rather than a general hospital. They warn that initial biopsy planning is critical to ensuring limb-sparing surgery remains possible later.
Verify Chinese medical quality by confirming a facility Tier 3A (Sanjia) status. This government ranking represents the highest level of safety and technology. Look for Joint Commission International (JCI) accreditation and doctors with Senior Physician (Zhuren Yishi) titles for complex sarcoma care.
Bookimed Expert Insight: Look beyond general cancer volume to find specialized leaders. Professor Dr. Liu Shi Xin at Xiamen Humanity Hospital holds elite State Council honors. This designation is rarer and more significant than standard hospital rankings for complex Ewing's sarcoma cases.
Patient Consensus: Patients emphasize asking for the team’s specific experience with primary bone sarcomas. They recommend getting a written multidisciplinary plan including chemotherapy and radiation before traveling.
Chinese oncology centers often integrate Traditional Chinese Medicine (TCM) with Western protocols. Integrated therapies focus on managing side effects. JCI-accredited facilities like Fuda Cancer Hospital use complementary techniques. These support recovery during bone resection and chemotherapy. Always coordinate with your specialist oncology team first.
Bookimed Expert Insight: Top Chinese oncology centers often focus on biological synergy. Fuda Cancer Hospital uses minimally invasive therapies like NanoKnife alongside TCM. This combination aims to manage advanced stages where standard chemo is difficult. Our data shows patients choose China specifically for this integrative multi-technology approach.
Patient Consensus: Patients emphasize using TCM only for comfort and appetite during treatment. They warn that herbs should never replace surgery or radiation for aggressive sarcomas.